Netherlands-based Pharming Group NV has achieved positive results for its protease inhibitor replacement therapy Ruconest for the prevention of hereditary angioedema (HAE), a rare disorder caused by a deficiency of the C1 esterase inhibitor protein. ---Subscribe to MedNous to access this article--- Clinical Research Company News
